CYTK (Cytokinetics) Total Liabilities : $1,537.05 Mil (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Total Liabilities?

Cytokinetics's Total Liabilities for the quarter that ended in Dec. 2024 was $1,537.05 Mil.

Cytokinetics's quarterly Total Liabilities increased from Jun. 2024 ($1,415.24 Mil) to Sep. 2024 ($1,449.97 Mil) and increased from Sep. 2024 ($1,449.97 Mil) to Dec. 2024 ($1,537.05 Mil).

Cytokinetics's annual Total Liabilities increased from Dec. 2022 ($1,122.68 Mil) to Dec. 2023 ($1,210.64 Mil) and increased from Dec. 2023 ($1,210.64 Mil) to Dec. 2024 ($1,537.05 Mil).

Cytokinetics Total Liabilities Historical Data

The historical data trend for Cytokinetics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Total Liabilities Chart

Cytokinetics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

420.42

597.46

1,122.68

1,210.64

1,537.05

Cytokinetics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															1,210.64	1,204.24	1,415.24	1,449.97	1,537.05

Cytokinetics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cytokinetics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	179.674	+	(758.179	+	599.192
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,537.05

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	1401.673	-	-135.372
	=	1,537.05

Cytokinetics's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	179.674	+	(758.179	+	599.192
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,537.05

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	1401.673	-	-135.372
	=	1,537.05

Cytokinetics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytokinetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (NAS:CYTK) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

KK3A:Germany KK3A:Germany

Address

350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.cytokinetics.com

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Executives

Wendall Wierenga	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
John T Henderson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Robert I Blum	officer: EVP, Corp. Development & CBO	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Fady Ibraham Malik	officer: SVP Research & Early Dev	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Andrew Callos	officer: EVP, Chief Commercial Officers	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Robert Arthur Harrington	director	C/O CYTOKINETICS, INCORPORATED, 350 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
B Lynne Parshall	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Robert Wong	officer: VP, Chief Accounting Officer	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ching Jaw	officer: SVP Finance & CFO	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Sandford D Smith	director	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Santo J Costa	director
Kaye Edward M. Md	director	3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Mark A Schlossberg	officer: SVP - Legal & General Counsel	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
David Cragg	officer: V.P., Human Resources	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080